Tetracyclo Ring System Having The Six-membered Hetero Ring As One Of The Cyclos Patents (Class 546/61)
  • Publication number: 20150148370
    Abstract: The invention described herein pertains to substituted indenoisoquinoline compounds as described herein, wherein RA, RD, W, X and Y are defined herein, pharmaceutical compositions and formulations comprising the indenoisoquinoline compounds, their synthesis, and methods for their use in the treatment and/or prevention of cancer.
    Type: Application
    Filed: May 24, 2012
    Publication date: May 28, 2015
    Applicant: PURDUE RESEARCH FOUNDATION
    Inventors: Mark S. Cushman, Yves George Pommier
  • Patent number: 9035055
    Abstract: An organic compound and a photoelectric conversion device containing the organic compound are disclosed. The organic compound and device realize high photoelectric conversion efficiency, low dark current and high-speed responsivity. It has been found that when this organic compound and an n-type semiconductor are used in combination, high-speed responsivity can be realized while maintaining high heat resistance, an aspect of which has not been seen when the connection part between a donor part and an acceptor part is a phenylene group.
    Type: Grant
    Filed: September 8, 2010
    Date of Patent: May 19, 2015
    Assignee: FUJIFILM Corporation
    Inventors: Mitsumasa Hamano, Katsuyuki Yofu, Tetsuro Mitsui, Kimiatsu Nomura
  • Publication number: 20150133445
    Abstract: The invention described herein pertains to the synthesis and use of certain N-substituted indenoisoquinoline compounds which inhibit the activity Tyrosyl-DNA Phosphodiesterase I (Tdp1) or Topoisomerase I (Top1) or both, or otherwise demonstrate anticancer activity. Also disclosed are novel N-substituted indenoisoquinoline compounds and pharmaceutical compositions comprising the novel N-substituted indenoisoquinoline compounds.
    Type: Application
    Filed: November 10, 2014
    Publication date: May 14, 2015
    Inventors: Mark S. CUSHMAN, Trung X. Nguyen, Martin M. Conda-Sheridan, Yves George Pommier
  • Patent number: 8999955
    Abstract: The invention relates to kinase inhibitors of the formula (I) in which —R1 to R4?H; ether or polyether, amino; NO2; NH-carbamate; NH—CO—R, with R such as defined above; N3 and derivatives thereof of the 1,2,3-triazole type; —R5=—OH; halogen; —OR with R such as defined above; OH-carbamate; OH-carbonate; NH2, NH-carbamate; NH—CO—R, with R such as defined above; N3 and derivatives thereof of the 1,2,3-triazole type; N(R9,R10); —R5??H or a C1-C12 alkyl, —R6?H; R; (R or R?)3—Si, with R such as defined above; optionally substituted aryl, heteroaryl; halogen (iodine); alkynyl; —R7 and R8?H, C1-C12 alkyl; —R9 and R10?H, R (or R?) such as defined above. These compounds can be used as kinase inhibitors in particular for treating cancer.
    Type: Grant
    Filed: January 19, 2009
    Date of Patent: April 7, 2015
    Assignee: Centre National de la Recherche Scientifique
    Inventors: Philippe Olivier Belmont, Laurent Meijer, Philip Cohen, Amaury Patin, Johann Bosson, Peter Gregory Goekjian
  • Publication number: 20150025067
    Abstract: Inhibitors of p67phox protein are provided herein, as well as pharmaceutical compositions and methods relating thereto.
    Type: Application
    Filed: February 13, 2013
    Publication date: January 22, 2015
    Applicant: CHILDREN'S HOSPITAL MEDICAL CENTER
    Inventors: Yi Zheng, Prakash Jagtap, Emily E. Bosco, Jaroslaw Meller, Marie-Dominique Filippi
  • Publication number: 20140374733
    Abstract: An object of the present invention is to provide a photoelectric conversion element having a photoelectric conversion film which exhibits heat resistance, a high photoelectric conversion efficiency, a low level of dark currents, rapid response, and sensitivity characteristics to red and can be produced by a vapor deposition processing that is continuously performed under a high-temperature condition. The photoelectric conversion element of the present invention is a photoelectric conversion element in which a conductive film, a photoelectric conversion film containing a photoelectric conversion material, and a transparent conductive film are laminated on one another in this order, wherein the photoelectric conversion material includes a compound represented by Formula (1).
    Type: Application
    Filed: September 5, 2014
    Publication date: December 25, 2014
    Applicant: FUJIFILM Corporation
    Inventors: Yuki HIRAI, Yosuke YAMAMOTO, Tomoaki YOSHIOKA, Eiji FUKUZAKI, Katsuyuki YOFU, Masaaki TSUKASE, Mitsumasa HAMANO, Takahiko ICHIKI
  • Patent number: 8912213
    Abstract: The invention described herein pertains to the synthesis and use of certain N-substituted indenoisoquinoline compounds which inhibit the activity Tyrosyl-DNA Phosphodiesterase I (Tdp1) or Topoisomerase I (Top1) or both, or otherwise demonstrate anticancer activity. Also disclosed are novel N-substituted indenoisoquinoline compounds and pharmaceutical compositions comprising the novel N-substituted indenoisoquinoline compounds.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: December 16, 2014
    Assignee: Purdue Research Foundation
    Inventors: Mark S. Cushman, Trung X. Nguyen, Martin M. Conda-Sheridan, Yves G. Pommier
  • Publication number: 20140336188
    Abstract: N-Substituted indenoisoquinoline compounds, and pharmaceutical formulations of N-substituted indenoisoquinoline compounds are described. Also described are processes for preparing N-substituted indenoisoquinoline compounds. Also described are methods for treating cancer in mammals using the described N-substituted indenoisoquinoline compounds or pharmaceutical formulations thereof.
    Type: Application
    Filed: July 24, 2014
    Publication date: November 13, 2014
    Applicants: PURDUE RESEARCH FOUNDATION, THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETSR
    Inventors: Mark S. CUSHMAN, Andrew E. MORRELL, Muthukaman NAGARAJAN, Yves G. POMMIER, Keli K. AGAMA, Smitha ANTONY
  • Publication number: 20140322767
    Abstract: The present invention relates to a droplet microreactor, i.e. a microreactor consisting of a droplet of a specific liquid, the microreactor being wall-less, wherein the interface of the specific liquid with the ambient environment and with the support on which the droplet is deposited defines the limits of the microreactor. The microreactor is characterized in that it consists of a droplet comprising at least one ionic liquid. The present invention also relates to methods for carrying out chemical or biochemical reactions and/or mixes using said droplet microreactor, and also to a lab-on-chip comprising a microreactor according to the invention.
    Type: Application
    Filed: May 6, 2014
    Publication date: October 30, 2014
    Inventors: Gilles MARCHAND, Françoise VINET, Guillaume DE LAPIERRE, Fatima HASSINE, Saïd GMOUH, Michel VAULTIER
  • Patent number: 8846924
    Abstract: The invention concerns the production of quinoline compounds containing sulfonic acid groups, the said quinoline compounds and their conversion into dyes containing sulfonic acid groups. The dyes according to the invention are used especially to label analytes, for example to label biomolecules.
    Type: Grant
    Filed: March 25, 2011
    Date of Patent: September 30, 2014
    Assignee: Atto-Tec GmbH
    Inventors: Alexander Zilles, Jutta Arden-Jacob, Karl-Heinz Drexhage, Norbert Uwe Kemnitzer, Monika Hamers-Schneider
  • Publication number: 20140284556
    Abstract: A 6H-indeno[2,1-b]quinoline derivative has a structure of formula (I). Each of Ar1 and Ar2 is a member selected from the group consisting of a substituted or non-substituted aryl group and a substituted or non-substituted heteroaryl group and R1 to R9 are substituents. The 6H-indeno[2,1-b]quinoline derivative of the present invention is provided with thermal stability. Chemical compounds of the present invention are adequate for the materials of the light-emitting layer of an OLED device with high device performance.
    Type: Application
    Filed: June 10, 2013
    Publication date: September 25, 2014
    Inventors: CHIEN-HONG CHENG, CHIN-HSIEN CHEN, LUN-CHIA HSU, YU-WEI CHANG, CHING-LIN CHAN
  • Patent number: 8829022
    Abstract: N-Substituted indenoisoquinoline compounds, and pharmaceutical formulations of N-substituted indenoisoquinoline compounds are described. Also described are processes for preparing N-substituted indenoisoquinoline compounds. Also described are methods for treating cancer in mammals using the described N-substituted indenoisoquinoline compounds or pharmaceutical formulations thereof.
    Type: Grant
    Filed: October 11, 2011
    Date of Patent: September 9, 2014
    Assignees: Purdue Research Foundation, The United States of America as represented by the Department of Health and Human Services
    Inventors: Mark S. Cushman, Andrew E. Morrell, Muthukaman Nagarajan, Yves G. Pommier, Keli K. Agama, Smitha Antony
  • Patent number: 8829023
    Abstract: The invention relates to a process for obtaining compounds derived from tetrahydro-?-carboline, specifically tadalafil and intermediate products from the synthesis, comprising the reaction between piperonal and an alkyl ester of D-tryptophan as a salt, and in the absence of any other component, followed by haloacetylation and a final cyclization with methylamine.
    Type: Grant
    Filed: February 10, 2012
    Date of Patent: September 9, 2014
    Assignee: Interquim, S.A.
    Inventors: Xavier Berzosa Rodríguez, Francisco Marquillas Olondriz
  • Patent number: 8822688
    Abstract: [Problem] To provide a compound useful as medicine having PDE4B inhibitory activity, in particular, as an active ingredient of a composition for treating or preventing schizophrenia, Alzheimer's disease, dementia, depression and the like. [Measures for Solution] The present inventors examined compounds having PDE4B inhibitory activity and found that a tricyclic or tetracyclic imidazo[1,2-a]pyridine derivative or salts thereof had a superior PDE4B inhibitory activity, thereby completing the present invention. The imidazo[1,2-a]pyridine derivative can be used as an agent for treating or preventing schizophrenia, Alzheimer's disease, dementia, depression and the like.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: September 2, 2014
    Assignee: Astellas Pharma Inc.
    Inventors: Kiyohiro Samizu, Naoyuki Masuda, Kazuhiko Iikubo, Yohei Koganemaru, Noriyuki Kawano, Junya Ohmori, Yasuyuki Mitani, Keni Ni
  • Patent number: 8741917
    Abstract: The present invention provides compounds of formula I: formula (I) wherein X1-X4 and R1-R12 have any of the values defined in the specification, as well as salts and prodrugs thereof, which inhibit major molecular mechanisms associated with bacterial cell division and proliferation so as to be useful for the treatment and/or prevention of bacterial infections. The invention also provides compositions comprising these compounds as well as methods for using these compounds to inhibit bacterial cell division and proliferation and to treat bacterial infections.
    Type: Grant
    Filed: January 15, 2010
    Date of Patent: June 3, 2014
    Assignee: Rutgers, The State University of New Jersey
    Inventors: Edmond J. LaVoie, Ajit Parhi, Daniel S. Pilch, Malvika Kaul
  • Patent number: 8729267
    Abstract: The present teachings generally relate to fluorescent dyes, linkable forms of fluorescent dyes, energy transfer dyes, reagents labeled with fluorescent dyes and uses thereof.
    Type: Grant
    Filed: June 21, 2011
    Date of Patent: May 20, 2014
    Assignee: Applied Biosystems, LLC
    Inventors: Ronald Graham, Ruiming Zou, Krishna G. Upadhya, Scott C. Benson
  • Patent number: 8686146
    Abstract: The invention described herein pertains to substituted azaindenoisoquinoline compounds, in particular 7-, 8-, 9-, and 10-azaindenoisoquinoline compounds, which are inhibitors of topoisomerase I, processes and intermediates for their syntheses, pharmaceutical compositions of the compounds, and methods of using them in the treatment of cancer.
    Type: Grant
    Filed: July 13, 2012
    Date of Patent: April 1, 2014
    Assignee: Purdue Research Foundation
    Inventors: Mark S. Cushman, Evgeny A. Kiselev, Andrew E. Morrell
  • Patent number: 8664238
    Abstract: Indenoisoquinolinone derivatives (I), the manufacturing method and the medical use thereof, which belong to pharmaceutical chemistry and organic chemistry field, are disclosed. These compounds can be used for treating several medical symptoms related to postmenopausal syndrome, uterine fibers deterioration and aortic smooth muscle cells proliferation, especially ER-(+) depend breast cancer. Meanwhile, these compounds can also be used for treating glioma and lung cancer, and have inhibiting effect on tumor metastasis effect on tumor metastasis.
    Type: Grant
    Filed: December 16, 2009
    Date of Patent: March 4, 2014
    Assignees: China Pharmaceutical University, Nanjing Medical University Affiliated Brain Hospital
    Inventors: Hua Xiang, Tianlin Wang, Hong Xiao, Qidong You, Yao Yao, Xiaobo Li, Qingjiang Liao
  • Patent number: 8629158
    Abstract: Novel MCH-1 receptor antagonists are disclosed. These compounds are used in the treatment of various disorders, including obesity, anxiety, depression, non-alcoholic fatty liver disease, and psychiatric disorders. Methods of making these compounds are also described in the present invention.
    Type: Grant
    Filed: July 1, 2010
    Date of Patent: January 14, 2014
    Assignee: Albany Molecular Research, Inc.
    Inventors: Peter R. Guzzo, Matthew David Surman, Alan John Henderson, Mark Hadden, Emily Elizabeth Freeman
  • Patent number: 8618123
    Abstract: Disclosed are novel gamma secretase inhibitors of the formula (I): or a pharmaceutically acceptable salt, solvate, or ester thereof, wherein L1, n, X, Ar, Y, Z, Q, and Q1 are as defined herein. Also disclosed are methods for inhibiting gamma secretase, methods for treating Alzheimer's disease, methods of treating one or more neurodegenerative diseases, and methods of inhibiting the deposition of amyloid protein (e.g., amyloid beta protein) in, on or around neurological tissue (e.g., the brain) using the compounds of formula 1.0.
    Type: Grant
    Filed: July 15, 2008
    Date of Patent: December 31, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Thavalakulamgara K. Sasikumar, Duane A. Burnett, Theodros Asberom, Wen-Lian Wu, Hongmei Li, Ruo Xu, Hubert B. Josien
  • Publication number: 20130345252
    Abstract: The invention described herein pertains to the synthesis and use of certain N-substituted indenoisoquinoline compounds which inhibit the activity Tyrosyl-DNA Phosphodiesterase I (Tdp1) or Topoisomerase I (Top1) or both, or otherwise demonstrate anticancer activity. Also disclosed are novel N-substituted indenoisoquinoline compounds and pharmaceutical compositions comprising the novel N-substituted indenoisoquinoline compounds.
    Type: Application
    Filed: March 15, 2013
    Publication date: December 26, 2013
    Inventors: MARK S. CUSHMAN, TRUNG X. NGUYEN, MARTIN M. CONDA-SHERIDAN
  • Publication number: 20130181202
    Abstract: There is provided a compound represented by a specific formula, which has an absorption maximum at 400 nm or more and less than 720 nm in a UV-visible absorption spectrum, wherein a molar extinction coefficient is 10,000 mol?1·l·cm?1 or more at the absorption maximum wavelength, and a difference between a melting point and a deposition temperature (a melting point?a deposition temperature) is 31° C. or more.
    Type: Application
    Filed: March 7, 2013
    Publication date: July 18, 2013
    Applicant: FUJIFILM CORPORATION
    Inventor: FUJIFILM CORPORATION
  • Publication number: 20130109713
    Abstract: The invention provides a compound of formula I:or a salt thereof, wherein R3-R8 and X and Y have any of the values described in the specification, as well as compositions comprising a compound of formula I. The compounds are useful as antibacterial agents.
    Type: Application
    Filed: June 24, 2011
    Publication date: May 2, 2013
    Inventors: Edmond J. Lavoie, Ajit Parhi, Daniel S. Pilch
  • Publication number: 20130102598
    Abstract: An indenoquinolone compounds of Formula (A) is disclosed, wherein the definition of each group is described in the description. These compounds may specifically inhibit topoisomerase I, and they have good activities against many kinds of human tumor cells, such as lung cancer, colon cancer, breast cancer, liver cancer and the like. They can be used in the manufacture of antitumor drugs. The method for preparing the compound of formula (A), and pharmaceutical compositions containing such compounds and the use in the manufacture of antitumor drugs are also disclosed.
    Type: Application
    Filed: May 17, 2011
    Publication date: April 25, 2013
    Applicant: SECOND MILITARY MEDICAL UNIVERSITY, PLA
    Inventors: Yunlong Song, Xiaodan Fu, Yunpeng Qi
  • Publication number: 20130085140
    Abstract: Indenoisoquinolinone derivatives (I), the manufacturing method and the medical use thereof, which belong to pharmaceutical chemistry and organic chemistry field, are disclosed. These compounds can be used for treating several medical symptoms related to postmenopausal syndrome, uterine fibers deterioration and aortic smooth muscle cells proliferation, especially ER-(+) depend breast cancer. Meanwhile, these compounds can also be used for treating glioma and lung cancer, and have inhibiting effect on tumor metastasis effect on tumor metastasis.
    Type: Application
    Filed: December 16, 2009
    Publication date: April 4, 2013
    Applicant: CHINA PHARMACEUTICAL UNIVERSITY
    Inventors: Hua Xiang, Tianlin Wang, Hong Xiao, Qidong You, Yao Yao, Xiaobo Li, Qingjiang Liao
  • Publication number: 20130023498
    Abstract: The present invention is a method for identifying agents which modulate microRNA activity. The invention involves contacting a cell harboring a microRNA and a microRNA binding sequence, which is operably linked to a nucleic acid molecule encoding a reporter protein, with a test agent and determining whether the test agent increases or decreases the expression of the reporter protein thereby identifying a microRNA modulator. Antagonists identified by this screening assay are provided, as are methods for using the same to inhibit microRNA activity and prevent or treat disease.
    Type: Application
    Filed: June 20, 2012
    Publication date: January 24, 2013
    Inventors: Qihong Huang, Alexander Deiters, Kiranmai Gumireddy
  • Publication number: 20120316342
    Abstract: This invention provides a therapeutic agent for hepatitis C comprising, as an active ingredient, a compound having anti-HCV activity useful in treatment of hepatitis C. The therapeutic agent for hepatitis C comprises, as an active ingredient, a compound represented by formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: January 31, 2011
    Publication date: December 13, 2012
    Inventors: Masanori Baba, Yuichi Hashimoto, Hiroshi Aoyama, Kazuyuki Sugita, Masahiko Nakamura, Atsushi Aoyama, Yasuo Urata
  • Publication number: 20120220610
    Abstract: The present invention relates to a method of reducing the production of glutamate from glutamine by glutaminase C in a cell or tissue. The method involves inhibiting glutaminase C activity in the cell or tissue under conditions effective to reduce production of glutamate from glutamine. Compounds for carrying out this method are also disclosed.
    Type: Application
    Filed: March 25, 2010
    Publication date: August 30, 2012
    Applicant: CORNELL UNIVERSITY
    Inventors: Richard A. Cerione, Jon W. Erickson, Kristin Wilson Cerione, Jianbin Wang
  • Patent number: 8217032
    Abstract: The present invention relates to a selective estrogen receptor modulator of formula I or Ia: (I) (Ia); or a pharmaceutical acid addition salt thereof; useful for treating vasomotor symptoms, in particular hot flashes, night sweats and other symptoms that affect women around menopause.
    Type: Grant
    Filed: June 23, 2011
    Date of Patent: July 10, 2012
    Assignee: Eli Lilly and Company
    Inventors: Robert Dean Dally, Jeffrey Alan Dodge, Scott Alan Frank, Ronald Jay Hinklin, Timothy Alan Shepherd, Owen Brendan Wallace
  • Patent number: 8202995
    Abstract: The present invention discloses novel pharmaceutically acceptable salts of aporphine compounds and carboxyl-group containing agents. Also, the present invention discloses methods for preparing the pharmaceutically acceptable salts. These pharmaceutically acceptable salts are suitable for use in treating and/or preventing hyperglycemic disease and/or several oxidative stress related diseases.
    Type: Grant
    Filed: June 19, 2009
    Date of Patent: June 19, 2012
    Assignee: Standard Chem. & Pharm. Co., Ltd.
    Inventors: Chin-Tsai Fan, Cheng-Shun Lai, Mei-Jung Lin
  • Publication number: 20120101119
    Abstract: N-Substituted indenoisoquinoline compounds, and pharmaceutical formulations of N-substituted indenoisoquinoline compounds are described. Also described are processes for preparing N-substituted indenoisoquinoline compounds. Also described are methods for treating cancer in mammals using the described N-substituted indenoisoquinoline compounds or pharmaceutical formulations thereof.
    Type: Application
    Filed: October 11, 2011
    Publication date: April 26, 2012
    Inventors: Mark S. Cushman, Andrew E. Morrell, Muthukaman Nagarajan, Yves G. Pommier, Keli K. Agama, Smitha Antony
  • Patent number: 8163912
    Abstract: The invention is directed to berberine compounds and processes for the preparation of berberine compounds through an intramolecular Bischler-Napieralski cyclization.
    Type: Grant
    Filed: September 29, 2009
    Date of Patent: April 24, 2012
    Assignee: Mallinckrodt LLC
    Inventors: Christopher W. Grote, Frank W. Moser, John E. Johnson
  • Patent number: 8119654
    Abstract: The present invention relates to Indenoisoquinolinone Analogs, compositions comprising an effective amount of an Indenoisoquinolinone Analog and methods for treating or preventing an inflammatory disease, a reperfusion injury, diabetes mellitus, a diabetic complication, reoxygenation injury resulting from organ transplantation, an ischemic condition, a neurodegenerative disease, renal failure, a vascular disease, a cardiovascular disease, cancer, a complication of prematurity, cardiomyopathy, retinopathy, nephropathy, neuropathy, erectile dysfunction or urinary incontinence, comprising administering to a subject in need thereof an effective amount of an Indenoisoquinolinone Analog.
    Type: Grant
    Filed: February 28, 2008
    Date of Patent: February 21, 2012
    Assignee: Inotek Pharmaceuticals Corporation
    Inventors: Prakash Jagtap, Duy-Phong Pham-Huu, Frederick Cohen, Xiaojing Wang
  • Publication number: 20120041016
    Abstract: The invention provides compositions comprising formula 1 steroids, e.g., 16?-bromo-3?-hydroxy-5?-androstan-17-one hemihydrate and one or more excipients, including compositions that comprise a liquid formulation comprising less than about 3% v/v water. The compositions are useful to make improved pharmaceutical formulations. The invention also provides methods of intermittent dosing of steroid compounds such as analogs of 16?-bromo-3?-hydroxy-5?-androstan-17-one and compositions useful in such dosing regimens. The invention further provides compositions and methods to inhibit pathogen replication, ameliorate symptoms associated with immune dysregulation and to modulate immune responses in a subject using the compounds. The invention also provides methods to make and use these immunomodulatory compositions and formulations.
    Type: Application
    Filed: July 14, 2011
    Publication date: February 16, 2012
    Inventor: James M. Frincke
  • Patent number: 8110575
    Abstract: The present invention relates to new CGRP-antagonists of general formula I wherein U, V, X, Y, R1, R2, R3 and R4 are defined as in the description, the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates, the mixtures thereof and the salts thereof and the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, medicaments containing these compounds, their use and processes for preparing them.
    Type: Grant
    Filed: November 21, 2008
    Date of Patent: February 7, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Dirk Gottschling, Georg Dahmann, Henri Doods, Annekatrin Heimann, Stephan Georg Mueller, Klaus Rudolf, Gerhard Georg Schaenzle, Dirk Stenkamp
  • Publication number: 20120022061
    Abstract: The present invention provides compounds of formula I: formula (I) wherein X1-X4 and R1-R12 have any of the values defined in the specification, as well as salts and prodrugs thereof, which inhibit major molecular mechanisms associated with bacterial cell division and proliferation so as to be useful for the treatment and/or prevention of bacterial infections. The invention also provides compositions comprising these compounds as well as methods for using these compounds to inhibit bacterial cell division and proliferation and to treat bacterial infections.
    Type: Application
    Filed: January 15, 2010
    Publication date: January 26, 2012
    Inventors: Edmond J. LaVoie, Ajit Parhi, Daniel S. Pilch, Malvika Kaul
  • Publication number: 20120012824
    Abstract: Disclosed is a metal complex compound represented by the following Chemical Formula 1, and an organic light emitting diode device including the same. In Chemical Formula 1, M, R1 to R8, A1 to A6, and y are the same as defined in the detailed description.
    Type: Application
    Filed: June 24, 2011
    Publication date: January 19, 2012
    Applicant: Samsung Mobile Display Co., Ltd.
    Inventors: Hamada Yuji, Kwan-Hee Lee
  • Publication number: 20120010177
    Abstract: The present invention is a method for identifying agents which modulate microRNA activity. The invention involves contacting a cell harboring a microRNA and a microRNA binding sequence, which is operably linked to a nucleic acid molecule encoding a reporter protein, with a test agent and determining whether the test agent increases or decreases the expression of the reporter protein thereby identifying a microRNA modulator. Antagonists identified by this screening assay are provided, as are methods for using the same to inhibit microRNA activity and prevent or treat disease.
    Type: Application
    Filed: August 1, 2011
    Publication date: January 12, 2012
    Applicant: The Wistar Institute / North Carolina State University
    Inventors: Qihong Huang, Alexander Deiters, Kiranmai Gumireddy
  • Publication number: 20110281847
    Abstract: The present invention relates to a selective estrogen receptor modulator of formula I or Ia: (I) (Ia); or a pharmaceutical acid addition salt thereof; useful for treating vasomotor symptoms, in particular hot flashes, night sweats and other symptoms that affect women around menopause.
    Type: Application
    Filed: June 23, 2011
    Publication date: November 17, 2011
    Applicant: ELI LILLY AND COMPANY
    Inventors: Robert Dean Dally, Jeffrey Alan Dodge, Scott Alan Frank, Ronald Jay Hinklin, Timothy Alan Shepherd, Owen Brendan Wallace
  • Patent number: 8053443
    Abstract: N-Substituted indenoisoquinoline compounds, and pharmaceutical formulations of N-substituted indenoisoquinoline compounds are described. Also described are processes for preparing N-substituted indenoisoquinoline compounds. Also described are methods for treating cancer in mammals using the described N-substituted indenoisoquinoline compounds or pharmaceutical formulations thereof.
    Type: Grant
    Filed: November 13, 2006
    Date of Patent: November 8, 2011
    Assignees: Purdue Research Foundation, The United States of America as represented by the Department of Health and Human Services
    Inventors: Mark S. Cushman, Andrew E. Morrell, Muthukaman Nagarajan, Yves G. Pommier, Keli K. Agama, Smitha Antony
  • Publication number: 20110190332
    Abstract: Trans-hexahydrobenzoaphenanthridines of the formula (I) wherein X, Y, R1, R2, R3, R4, R5, R6, and R7 are as defined herein, are disclosed. Pharmaceutical formulations including such compounds, and methods of using such compounds for treating a patient suffering from dopamine-related dysfunction of the central or peripheral nervous system are also disclosed.
    Type: Application
    Filed: July 31, 2009
    Publication date: August 4, 2011
    Applicant: EFFIPHARMA
    Inventor: Richard B. Mailman
  • Patent number: 7985602
    Abstract: The present teachings generally relate to fluorescent dyes, linkable forms of fluorescent dyes, energy transfer dyes, reagents labeled with fluorescent dyes and uses thereof.
    Type: Grant
    Filed: August 14, 2007
    Date of Patent: July 26, 2011
    Assignee: Applied Biosystems, LLC
    Inventors: Ronald J. Graham, Ruiming Zou, Krishna G. Upadhya, Scott C. Benson
  • Patent number: 7956187
    Abstract: 8-Substituted-2,6-methano-3-benzazocines of general structure I in which A is —CH2OH, —CH2NH2, —NHSO2CH3, Q is O or S and Y is O, S or NOH are useful as analgesics, anti-diarrheal agents, anticonvulsants, antitussives and anti-addiction medications.
    Type: Grant
    Filed: October 10, 2008
    Date of Patent: June 7, 2011
    Assignee: Rensselaer Polytechnic Institute
    Inventor: Mark P. Wentland
  • Publication number: 20110092533
    Abstract: The current invention is in the field of molecular biology/pharmacology and provides compounds which modulate the effects of GPR30 as well as the classical estrogen receptors alpha and beta (ER? and ER?). These compounds may function as agonists and/or antagonists of one or more of the disclosed estrogen receptors.
    Type: Application
    Filed: December 14, 2010
    Publication date: April 21, 2011
    Applicant: STC. UNM
    Inventors: Eric R. PROSSNITZ, Sergey E. Tkatchenko, Chetana M. Revankar, Larry A. Sklar, Jeffrey B. Arterburn, Daniel F. Cimino, Tudor I. Oprea, Cristian-George Bologa, Bruce S. Edwards, Alexander Kiselyov, Susan M. Young
  • Patent number: 7928236
    Abstract: The subject of the present invention is to provide a fluorescent substance excitable under visible light, having higher photostability and a long fluorescence lifetime. Another subject is to provide a fluorescent substance consists of a non-natural amino acid applicable to peptide synthesis systems. Searching fluorescent substances, which are fluorescent amino acids and excitable under visible light, having the lowest possible molecular weight for a high photostability resulted in forming a condensed polycyclic aromatic compound by subjecting a compound having an acridone structure to substitution with an amino acid and further condensation with a benzene ring. Thus, the subject is achieved by the fluorescent substance consisting of amino acid-substituted benzoacridone derivative excitable under visible light.
    Type: Grant
    Filed: June 8, 2006
    Date of Patent: April 19, 2011
    Assignee: National University Corporation Okayama University
    Inventors: Masumi Taki, Masahiko Sisido
  • Publication number: 20110056562
    Abstract: A compound represented by the following formula (I), and a photoelectric conversion device containing the compound: wherein Z1 is a ring containing two carbon atoms and represents a 5-membered ring, a 6-membered ring or a condensed ring containing at least either a 5-membered ring or a 6-membered ring, each of L1, L2 and L3 independently represents an unsubstituted methine group or a substituted methine group, n represents an integer of 0 or more, each of R1, R2, R3, R4, R5 and R6 independently represents a hydrogen atom or a substituent, R1 and R2, R2 and R3, R4 and R5, or R5 and R6 may be combined with each other to form a ring, and each of R21 and R22 independently represents a substituted aryl group, an unsubstituted aryl group, a substituted heteroaryl group or an unsubstituted heteroaryl group, provided that the case where both R21 and R22 are an unsubstituted phenyl group is excluded.
    Type: Application
    Filed: September 8, 2010
    Publication date: March 10, 2011
    Applicant: FUJIFILM CORPORATION
    Inventors: Mitsumasa HAMANO, Katsuyuki YOFU, Tetsuro MITSUI, Kimiatsu NOMURA
  • Patent number: 7858627
    Abstract: The invention provides compounds of formula I or formula II: wherein: the bond represented by is a single bond or a double bond, and R1—R5, X, and Y have any of the meanings defined in the specification and their pharmaceutically acceptable salts. The invention also provides pharmaceutical compositions comprising a compound of formula I or II, processes for preparing compounds of formula I or II, intermediates useful for preparing compounds of formula I or II, and therapeutic methods for treating cancer and other topoisomerase related conditions using compounds of formula I or II.
    Type: Grant
    Filed: April 13, 2009
    Date of Patent: December 28, 2010
    Assignee: Rutgers, The State University of New Jersey
    Inventors: Edmond J. LaVoie, Alexander L. Ruchelman, Leroy F. Liu
  • Patent number: 7847125
    Abstract: A compound having the formula: R1 and R2 together with the carbon atoms to which they are bonded are joined together to form a C3-C30 ring. The C3-C30 ring may be substituted with one or more substituents or unsubstituted. The C3-C30 ring may contain one or more heteroatoms. The C3-C30 ring may be saturated, partially unsaturated, or fully unsaturated.
    Type: Grant
    Filed: November 16, 2007
    Date of Patent: December 7, 2010
    Assignee: Chemtura Corporation
    Inventors: Qinggao Ma, Cyril Migdal
  • Patent number: 7838703
    Abstract: A diaromatic amine compound having the general formula: wherein R1 and R2 together with the carbon atoms to which they are bonded are joined together to form a C3-C30 ring, and R3 is an allyl, benzyl, or methallyl group. R4, R5, and R6 are independently hydrogen, C1-C30 alkyl group, C2-C30 alkenyl group, C3-C12 cycloalkyl group, C5-C25 aryl group, C6-C25 arylalkyl group, or C1-C30 alkoxy group.
    Type: Grant
    Filed: November 16, 2007
    Date of Patent: November 23, 2010
    Assignee: Chemtura Corporation
    Inventors: Qinggao Ma, Cyril Migdal
  • Patent number: 7829567
    Abstract: Disclosed herein are novel imino-indeno[1,2-c]quinoline derivatives of formula (I): or a pharmaceutically acceptable salt or solvate thereof, wherein each of the substituents is given the definition as set forth in the Specification and Claims. Also disclosed are the preparation processes of these derivatives, their synthetic precursors and their uses in the manufacture of pharmaceutical compositions for use in the treatment of cancers.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: November 9, 2010
    Assignee: Kaohsiung Medical University
    Inventors: Cherng-Chyi Tzeng, Yeh-Long Chen, Chih-Hua Tseng, Pei-Jung Lu